Abstract:Introduction. Post-acute sequelae of COVID-19 (PASC) is causing a silent pandemic in the U.S. Gulf South, a part of flyover U.S. where patients are quietly withdrawing from the workforce and largely disconnected from the advocacy resources growing in more affluent regions[1]. To date, there is no clinical test to diagnose PASC and PASC risk factors and etiology remain unclear. Methods. This prospective study investigates PASC alongside pre-COVID-19 medical history, acute COVID-19 course, and a panel of 25 blood biomarkers collected from 100 COVID-19 patients in New Orleans, LA, in a 52.5% Black cohort, providing a unique opportunity to describe PASC symptoms and associations within a comorbidity-rich population. 107 participants recruited from the ClinSeqSer COVID-19 study at University Medical Center (UMC) or Tulane Medical Center (TMC) in New Orleans underwent PASC symptom questionnaires at 3-month intervals. 100 blood samples from patients at their initial post-COVID follow-up visit were analyzed for cardiac, metabolic, inflammatory, coagulation, chemistry, and hematologic markers in a clinical laboratory. Results were analyzed in SPSS for associations with PASC positivity which was defined as presence of three or more new-since-COVID symptoms present at a visit 12 or more weeks after COVID diagnosis. PASC prevalence was also analyzed alongside demographics and past medical history. Results. Enrolled participants ranged from 21-87 years old (median 53, mean 52.1, STD 13.7). 63% of participants were female, 52.5% Black, 44% White, and 3% Asian. 52% of participants were hospitalized during their acute COVID-19 course. Severity of participants' prior acute COVID was known for most subjects. For 82% of subjects, nasal swab and or saliva SARS CoV-2 qRT-PCR value was known and PCR values did not predict later PASC. Maximum severity scores were assigned to 100 out of 105 participants from whom acute COVID-19 data was collected. On average, patients reported over 5 new-since-COVID symptoms and 75% of patients who completed a questionnaire at time of blood draw were PASC positive. Questionnaire results identified common new-since-COVID symptoms including fatigue (64%), dyspnea (53%), myalgias (48%), trouble concentrating (48%), and memory problems (50%). Over one third of participants reported new-since-COVID arthralgias (34%), headaches (40%), and problems sleeping (40%). For all patients reporting these common symptoms, average frequency and severity of symptoms were reported on a scale of 1 (mild) to 5 (severe) as follows (frequency; severity): fatigue (3.3; 3.3), myalgia (3.4, 3.4), memory problems (3.1, 3.2). Comparison of means analysis indicates that hemoglobin, hematocrit and calcium are lower in PASC positive patients but still within normal range. Analysis of demographics indicates that females in this study are 4.8 times more likely to be classified as PASC positive than males. Serology identified a mild trend toward higher anti-N concentration, and plasma proximity extension proteome detected higher IL-6 and TNF, among PASC vs non-PASC. Discussion. PASC is highly prevalent among post-COVID subjects in this 52.5% Black cohort. A panel of commonly ordered clinical labs was unable to distinguish PASC vs non-PASC subjects, indicating an ongoing need for diagnostic biomarkers relevant across diverse patient groups.

Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19

Cytokine Profile in Patients with Postacute Sequelae of COVID-19

No reduced serum serotonin levels in patients with post-acute sequelae of COVID-19

High Somatization Rates, Frequent Spontaneous Recovery, and a Lack of Organic Biomarkers in Post‐Covid‐19 Condition

"Inflammatory Pathways in Patients with Post-acute Sequelae of COVID-19 - The Role of the Clinical Immunologist"

Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

POST-ACUTE SEQUELAE OF COVID-19: CHARACTERIZATION, COMORBIDITIES, AND BIOMARKERS IN A DIVERSE COHORT

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Relationship between plasma cortisol concentration and Long COVID symptoms in the post-acute phase of COVID-19: a cross-sectional study and recommendations for future research

High Levels of IL-1β, TNF-α and MIP-1α One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients

Clinical usefulness of the serum levels of neuroinflammatory and lung fibrosis biomarkers in the assessment of cognitive dysfunction in post-COVID19 patients

PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females

Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19

Investigating viral and autoimmune T cell responses associated with post-acute sequelae of COVID-19

Multiple early factors anticipate post-acute COVID-19 sequelae

Cardiovascular symptoms of PASC are associated with trace-level cytokines that affect the function of human pluripotent stem cell derived cardiomyocytes

Precision symptom phenotyping identifies early clinical and proteomic predictors of distinct COVID-19 sequelae

Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19

1135 Predictors of Post-COVID Clinical and Cognitive Consequences

Dysregulated Inflammatory Cytokine Levels May Be Useful Markers in a Better Up-Dated Management of COVID-19